The effects of postmenopausal hormone replacement therapy on hemostatic variables: A meta-analysis of 46 studies

Gynecological Endocrinology

Volumn 16, Issue 4, 2002, Pages 335-346

  Acs, N ^a   Vajo, Z ^b   Miklos, Z ^a   Siklosi, G ^a   Paulin, F ^a   Felicetta, J V ^b   Szekacs B ^c  

^a National Institute of Oncology   (Hungary)

^b CARL T HAYDEN VA MEDICAL CENTER   (United States)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Coagulation; Fibrinogen; HRT; Protein C; Protein S; Thrombosis

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 8; ESTROGEN; FIBRINOGEN; GESTAGEN; PLASMINOGEN; PROTEIN C; PROTEIN S;

ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; SIDE EFFECT; VEIN THROMBOSIS;

EID: 0036694014     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/gye.16.4.335.346     Document Type: Article

References (93)

1. Randomized trial of estrogen plus progestin for secondary, prevention of coronary heart disease in postmenopausal women
2. Hormone replacement therapy and cardiovascular disease
3. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women
4. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence
5. Hormone therapy to prevent disease and prolong life in postmenopausal women
6. Hormone replacement therapy and the risk of stroke
7. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
8. Cardio-protective effects of individual conjugated equine estrogens through their possible modulation of insulin resistance and oxidation of low-density lipoprotein
9. How do we explain the clinical benefits of estrogen?
10. Risk of venous thromboembolism, in users of hormone replacement therapy
11. Risk of hospital admission for idiopathic venous thromboembolism in users of hormone replacement therapy
12. Prospective study of exogenous hormones and risk of pulmonary embolism in women
13. Assessment of the risk for venous thromboembolism among users of hormone replacement therapy
14. Blood coagulation in postmenopausal women given estrogen treatment: Comparison of transdermal and oral administration
15. Fibrinogen as a risk factor for stroke and myocardial infarction
16. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study
17. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis
18. The fibrinolytic enzyme system and its role in the etiology of thrombo-embolic disease
19. Endogenous tissue-type plasminogen activator and risk of myocardial infarction
20. Familial venous thrombophilia
21. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency
22. Increased activation of the hemostatic system in men at high risk of fatal coronary heart disease
23. Hormone replacement therapy and hemostatic function
24. Epidemiology of coagulation factors, inhibitors and activation markers. The Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use
25. Estrogen use and all-cause mortality
26. Postmenopausal estrogen use and heart disease risk factors in the 1980s
27. The effects of ovariectomy and oestrogen replacement on small artery biomechanics in the rat
28. Fibrinogen and risk of cardiovascular disease: The Framingham Study
29. Hemostatic variables and menopausal status: Influence of hormone replacement therapy
30. Tissue factor interactions with factor VII: Measurement and clinical significance of factor VIIa in plasma
31. Correlation of factor VII activity, and antigen with cholesterol and triglycerides in healthy young adults
32. Factor VII hyperactivity in acute myocardial thrombosis. A relation to the coagulation activation
33. Menopausal status and hemostatic variables
34. The ratio of factor VIII-related antigen and factor VIII biologic activity as an index of hypercoagulability and intravascular clotting
35. Factor VIII on the vascular intima: Possible importance in haemostasis and thrombosis
36. Plasminogen activator inhibitor I and atherothrombosis
37. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
38. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: A 7 year follow up
39. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity
40. Plasma fibrinogen in women: Relationships with oral contraception, the menopause and hormone replacement therapy
41. The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status
42. Estrogen replacement therapy and coagulation: Relationship to lipid and lipoprotein changes
43. Plasma fibrinogen levels in healthy postmenopausal women: Physical activity and hormone replacement status
44. Thrombosis and hormone replacement therapy in postmenopausal women
45. Unstable angina/myocardial infarction/atherosclerosis: Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study
46. Fibrinogen and plasminogen modifications during oral estradiol replacement therapy
47. Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women
48. Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women
49. Hemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women
50. Transdermal estrogen replacement therapy: Beneficial effects on hemostatic risk factors for cardiovascular disease
51. Differential AT III-response to oral and parenteral administration of 17β-estradiol
52. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors
53. The effects of transdermal oestradiol and oral progestagens on haemostasis variables
54. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women
55. Biologic effects of transdermal estradiol
56. Combination estrogen and progestogen replacement therapy does not adversely affect coagulation
57. Coagulation and fibrinolysis in estrogen-treated surgically postmenopausal women
58. Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women
59. Coagulation activation following estrogen administration to postmenopausal women
60. Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly
61. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables
62. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: A 1-year, double-blind, placebo-controlled study
63. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM
64. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
65. A 2-year study on the beneficial effects of 17β-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: No additional unfavourable effects of dydrogesterone
66. Population correlates of coagulation factor VII. Importance of age, sex and menopausal status as determinants of activated factor VII
67. Effect of transdermal oestradiol on the hemostatic balance of menopausal women
68. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women
69. Effects of estrogen replacement therapy on thrombin generation
70. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: A placebo-controlled study with nomegestrol acetate and estradiol
71. Transdermal estroprogestins versus transdermal estrogen plus oral dihydrogesterone replacement in menopause
72. Medical Research Council's General Practice Research Framework. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy
73. Factor VIII:C relationships to selected lipids, age, and gender in healthy adults
74. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: A randomized controlled trial
75. Metabolic effect of two hormonal preparations in postmenopausal women
76. Beneficial effects on serum lipoproteins by 17β-oestradiol-dydrogesterone therapy in postmenopausal women; a prospective study
77. Lipoprotein(a) levels and isoforms and fibrinolytic activity in postmenopause - Influence of hormone replacement therapy
78. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women
79. The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women
80. Association of hormone replacement therapy with hemostatic and other cardiovascular risk factors
81. Long term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): A randomised study
82. Effect of hormone replacement therapy on anti-thrombin III activity in post menopausal women
83. The effect of two regimens of hormone replacement therapy on the hemostatic profile in postmenopausal women
84. Preoperative plasma levels of prothrombin fragment 1 + 2 correlate with the risk of venous thrombosis after elective hip replacement
85. Thrombogenic factors and recurrent coronary events
86. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile
87. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans
88. Cell-associated plasminogen activation: Regulation and physiologic functions
89. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls
90. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries
91. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
92. Measuring plasma fibrinogen to predict stroke and myocardial infarction: An update